홈MCP워크벤치Skills
홈워크벤치알림마이페이지
llms.txt · MCP 가이드개인정보처리방침 · 이용약관 · 지원v1.8.3
  1. 홈
  2. /화합물

아세토히드록삼 산

Acetohydroxamic Acid

HCID 1990
새 반응
인쇄

데이터를 보충하는 중입니다. 잠시 후 페이지를 새로 고치면 최신 내용을 볼 수 있습니다

기본 정보개요이름 및 식별자물성안전 및 규제화학 및 산업관련 반응화합물 노트
부분 구조 검색유사 구조 찾기

기본 정보

CAS
546-88-3
표준 SMILES
CC(=O)NO
InChIKey
RRUDCFGSUDOHDG-UHFFFAOYSA-N
분자식
C2H5NO2
평균 분자량
75.07 g/mol
단동위원소 질량
75.0320284

개요

Acetohydroxamic Acid can cause developmental toxicity according to state or federal government labeling requirements.

이름 및 식별자

우선 이름
Acetohydroxamic Acid
IUPAC
N-hydroxyacetamide
현지명
아세토히드록삼 산
영어명
Acetohydroxamic acid
분자식
C2H5NO2
분자량
75.07

이름 및 동의어

acetohydroxamic acidN-Hydroxyacetamide546-88-3Acetylhydroxamic acidLithostatAcetic acid, oximeMethylhydroxamic acidAcetohydroximic acidN-AcetylhydroxylamineAcethydroxamsaeurecetohyroxamic acidN-Acetyl hydroxyacetamide
이름 더 보기
아세토하이드록사믹산아세토히드록삼산아세토히드록삼산(ACETOHYDROXAMICACID)AHAAcetylhydroxylamineAcetomenadioneN-hydroxyacetimidic acidT-41BNSC 5073yangwosuan
Acido acetohidroxamicoAcide acetohydroxamiqueAcidum acetohydroxamicumn-hydroxy-acetamideDTXSID7022546NSC-1761364RZ82L2GY5DTXCID802546

데이터베이스 식별자

CAS
546-88-3
PubChem CID
1990
DTXSID
DTXSID7022546
ChEMBL
CHEMBL734
ChEBI
CHEBI:27777
UNII
4RZ82L2GY5
EC Number
208-913-8
Nikkaji
J23.285H

물성

구조 계산 물성보충 중

XLogP
-1.6
극성 표면적
49.3 Ų
수소 결합 공여자 수
2
수소 결합 수용자 수
2
회전 가능 결합 수
0
무거운 원자 수
5
형식 전하
0
복잡도
42.9

실험 및 물리화학적 성질

DrugsPharmaceuticals -> Listed in ZINC15
pH9.39 (aq soln)
SpringerMaterials PropertiesChemical shift
LogP · 3건

log Kow= -1.59

-0.7

-1.59

Solubility · 2건

5.09e+02 g/L

<0.2 [ug/mL] (The mean of the results at pH 7.4)

Human Drugs · 2건

FDA approved drugs -> Active ingredient

FDA approved drugs -> Active ingredient

DecompositionWhen heated to decomposition it emits toxic fumes of nitroxides.
Melting Point · 2건

89-92 °C

90.5 °C

Physical DescriptionSolid
Dissociation Constants · 2건

8.7 (at 25 °C)

pKa= 8.70

안전 및 규제

안전 정보는 참고용이며, 공급업체의 물질안전보건자료(SDS), 관련 법규 및 전문가 평가를 대체하지 않습니다.

GHS 분류

GHS Classification · 4건

Danger

H360 (96.1%): May damage fertility or the unborn child [Danger Reproductive toxicity]

P203, P280, P318, P405, and P501 (click each P-code to see the statement)

Aggregated GHS information provided per 51 reports by companies from 9 notifications to the ECHA C&L Inventory.

유해성 정보

Regulatory InformationHazard Traits - Developmental Toxicity
FDA Requirements · 1건

Manufacturers, packers, and distributors of drug and drug products for human use are responsible for complying with the labeling, certification, and usage requirements as prescribed by the Federal Food, Drug, and Cosmetic Act, as amended (secs 201-902, 52 Stat. 1040 et seq., as amended; 21 U.S.C. 321-392).

Hazard Classes and CategoriesRepr. 1B (96.1%)

안전 및 보호

Disposal Methods · 1건

SRP: At the time of review, criteria for land treatment or burial (sanitary landfill) disposal practices are subject to significant revision. Prior to implementing land disposal of waste residue (including waste sludge), consult with environmental regulatory agencies for guidance on acceptable disposal practices.

독성 정보

Interactions · 3건

Concurrent use of alcoholic beverages with acetohydroxamic acid has resulted in a nonpruritic, reddish, macular skin rash about 30 to 45 minutes after ingestion. The rash may be associated with a general feeling of warmth and tingling, and usually disappears spontaneously in 30 to 60 minutes.

화학 및 산업

약리 정보

ATC Code · 2건

G - Genito urinary system and sex hormones

QG - Genito urinary system and sex hormones

Protein BindingNo known binding
Pharmacodynamics · 1건

Acetohydroxamic Acid, a synthetic drug derived from hydroxylamine and ethyl acetate, is similar in structure to urea. In the urine, it acts as an antagonist of the bacterial enzyme urease. Acetohydroxamic Acid has no direct antimicrobial action and does not acidify urine directly.

Mechanism of Action · 2건

Acetohydroxamic Acid reversibly inhibits the bacterial enzyme urease. This inhibits the hydrolysis of urea and production of ammonia in urine infected with urea-splitting organisms, leading to a decrease in pH and ammonia levels. As antimicrobial agents are more effective in such conditions, the effectiveness of these agents is amplified, resulting in a higher cure rate.

Inhibits the hydrolysis of urea and production of ammonia in urine infected with urea-splitting bacteria, by reversible inhibition of the bacterial enzyme urease, and by the chelation of nickel, an essential component of urease enzymes. Such enzyme inhibition results in reduction of both urine alkalinity and ammonia concentration. The effectiveness of antibacterial medication is then enhanced and the formation of urinary calculi reduced.

Biological Half-Life · 2건

5-10 hours in patients with normal renal function

...increases with increasing dose and reportedly ranges from about 3.5-10 hours in patients with normal renal function.

Metabolism/Metabolites · 2건

35-65% of oral dose excreted unchanged in urine (which provides the drug's therapeutic effect).

...is metabolized to acetamide.

FDA Pharmacological Classification · 6건

4RZ82L2GY5

ACETOHYDROXAMIC ACID

Established Pharmacologic Class [EPC] - Urease Inhibitor

관련 반응

55건
반응 기록 만들기
HRID 16396 반응식
HRID 16396반응물로
HRID 82191 반응식
HRID 82191반응물로
HRID 82777 반응식
HRID 82777반응물로
HRID 241954 반응식
HRID 241954반응물로
HRID 243823 반응식
HRID 243823반응물로
HRID 245354 반응식
HRID 245354반응물로
HRID 423274 반응식
HRID 423274반응물로
HRID 475021 반응식
HRID 475021반응물로
이전1 / 7 페이지

화합물 노트

이 페이지에서기본 정보개요이름 및 식별자물성안전 및 규제화학 및 산업관련 반응화합물 노트

물리화학적 성질

녹는점
88 · 88-90 °C (lit.)
끓는 점
133.7 °C · 133.7°C (rough estimate)
밀도
1.2269 · 1.2269 (rough estimate)
굴절률
1.4264 · 1.4264 (estimate)
저장 조건
Keep in dark place,Inert atmosphere,Room temperature
용해도
메탄올(약간 용해됨), 물(약간 용해됨)
물리적 상태
결정질 고체
산도 계수 (pKa)
8.7 · 8.70(at 25℃)
색상
흰색에서 연한 노란색
수용성
물에 용해됩니다.
Merck
14 · 14,63
BRN
1739019 · 1739019
안정성
수분 및 온도에 민감함
InChI
1S/C2H5NO2/c1-2(4)3-5/h5H,1H3,(H,3,4)
InChIKey
RRUDCFGSUDOHDG-UHFFFAOYSA-N
SMILES
CC(NO)=O
NIST
Acetamide,N-hydroxy(546-88-3)
EPA
Acetohydroxamic acid (546-88-3)

화학적 성질

White Crystalline Solid

Acetohydroxamic acid chelates iron and possibly other heavy metals with concurrent oral administration; this may result in reduced intestinal absorption of both; if iron therapy is indicated, parenteral administration of iron is recommended.

In vitro studies indicate that acetohydroxamic acid and methenamine have a synergistic effect in inhibiting increases in pH caused by urease-producing Proteus spp. and that acetohydroxamic acid potentiates the antibacterial effect of methenamine against these bacteria...

Human Toxicity Excerpts · 2건

Acetohydroxamic acid was positive for mutagenicity in the Ames test.

Acetohydroxamic acid overdose has not been reported. However, if it should occur, concomitant reduction in platelets and/or white blood cells should be anticipated; reticulocyte count is likely to be elevated, and severe hemolysis may occur.

Drug Induced Liver Injury · 6건

Drug Induced Liver Injury Rank (DILIrank 2.0)

Acetohydroxamic acid

Ambiguous-DILI-concern

3

Warnings & precautions

DOI:10.1016/j.drudis.2016.02.015

Non-Human Toxicity Excerpts · 3건

Acetamide, a metabolite or acetohydroxamic acid, has been shown to cause hepatocellular carcinoma in rats when used in very high doses.

...in long-term studies in rats, large oral dosages (e.g., 4 g/kg daily) of acetamide, a metabolite of acetohydroxamic acid, have been shown to cause hepatocellular carcinoma.

Evidence of toxicity did not occur when the drug was administered subcutaneously in mice at a dosage of 500 mg/kg daily for 60-100 days; however, evidence of cumulative toxicity, with death occurring at a mean of 21 days, occurred when the drug was administered subcutaneously at a dosage of 1 g/kg daily.

Antidote and Emergency Treatment · 1건

Treatment of overdose: Administration should be stopped. There is no known specific antidote for acetohydroxamic acid overdose. Recommended treatment consists of the following: Monitoring - Close monitoring of hematologic status; Specific Treatment - Symptomatic treatment as necessary. Blood transfusions if required. Dialysis (considered possible but not yet proven).

Non-Human Toxicity Values · 3건

LD50 Mouse ip 2.5 g/kg

LD50 Mouse oral 5 g/kg

LD50 Rat oral 4.8 g/kg

규제 정보

FDA Requirements · 1건

Manufacturers, packers, and distributors of drug and drug products for human use are responsible for complying with the labeling, certification, and usage requirements as prescribed by the Federal Food, Drug, and Cosmetic Act, as amended (secs 201-902, 52 Stat. 1040 et seq., as amended; 21 U.S.C. 321-392).

안전 데이터

wgk
3
rtecs
AK8157000
ridadr
3263
독성
mmo-sat 160 mmol/plate JOPHDQ 3,557,80
HS 번호
29225090
risk_code
61-40
hazard_code
T
safety_code
53-45-36/37/39-22
포장분류
II
기존화학 물질
KE-00066
위험 참고 사항
Toxic
Hazard Classifications
Repr. 1B
스토리지 클래스
6.1C - Combustible acute toxic Cat.3toxic compounds or compounds which causing chronic effects
유해 물질 데이터
546-88-3(Hazardous Substances Data)

Mechanisms of Action [MoA] - Urease Inhibitors

Acetohydroxamic acid is an Urease Inhibitor. The mechanism of action of acetohydroxamic acid is as an Urease Inhibitor.

ACETOHYDROXAMIC ACID

MeSH Pharmacological ClassificationCompounds or agents that combine with an enzyme in such a manner as to prevent the normal substrate-enzyme combination and the catalytic reaction.
Absorption, Distribution and Excretion · 6건

Well absorbed from the GI tract following oral administration.

Well absorbed from gastrointestinal tract.

Well distributed throughout body fluids.

Elimination: Renal- Unchanged, 36 to 65%; as acetamide, 9 to 14%. Respiratory - As carbon dioxide, 20 to 40%.

In rodents, about 55% of an intraperitoneal dose is excreted in urine as unchanged drug, 15% as acetamide, and 10% as acetate within 24 hours; approximately 7% of the dose is excreted by the lungs as carbon dioxide and less than 1% is excreted in feces within 24 hours.

In mice, highest concentrations of the drug occur in the liver and kidney, while the lowest concentrations occur in the brain.

Cellular LocationsCytoplasm

용도 및 제조

UsesMEDICATION
응용 분야 · 3건

개요Acetohydroxamic acid is a potent, non-competitive and irreversible inhibitor of bacterial urease (Ki≈lO-7M). This enzyme, which is widely distributed in plants and bacteria, but not in mammalian cells, catalyzes the decomposition of urea to ammonia. Elevated urinary ammonia levels can reduce the antibacterial effectiveness of a number of agents. Thus, acetohydroxamic acid is useful as adjunctive therapy to decrease urinary ammonia and alkalinity in patients with chronic urea-splitting urinary infection. Such infections are a leading cause of recurring complications and death in paraplegics.

용도Acetohydroxamic acid is a potent inhibitor of bacterial urease activity and reduces urinary ammonia levels. 2-Acetohydroxamic acid loaded floating microspheres forms an efficient drug delivery system for the treatment of Helicobacter pylori.Acetohydroxamic acid was used:to study the mechanism of complexation of iron (III) with acetohydroxamic acid.to study the inhibitory mechanism of lansoprazole and omeprazole on Helicobacter pyloni.in urease inhibition studies.for in situ generation of nitrosocarbonylmethane as a Diels-Alder dienophile.Used in urease inhibition studies and for in situ generation of nitrosocarbonylmethane as a Diels-Alder dienophile.

일반 설명Acetohydroxamic acid is a potent inhibitor of bacterial urease activity and reduces urinary ammonia levels. 2-Acetohydroxamic acid loaded floating microspheres forms an efficient drug delivery system for the treatment of Helicobacter pylori.

상·하류 제품 정보

상류 원료

히드록실아민

하류 제품

아세트알독심카라세마이드5-(트리플루오로메틸)벤조[d]이속사졸-3-아민